Quantitative Immunoglobulins (IgG, IgA, IgM): When to Order, What the Patterns Mean, and the Myeloma Connection

Quantitative Immunoglobulins (IgG, IgA, IgM): When to Order, What the Patterns Mean, and the Myeloma Connection

Recurrent infections, monoclonal spikes, and the difference between too much of one and not enough of everything else.

The Three Immunoglobulins

• IgG (700–1600 mg/dL): The workhorse—75% of serum immunoglobulins. Provides long-term immunity after infection or vaccination. Crosses the placenta (maternal IgG protects the newborn). Low IgG = increased risk of bacterial infections.
• IgA (70–400 mg/dL): Mucosal immunity—found in saliva, tears, respiratory and GI secretions. Selective IgA deficiency is the most common primary immunodeficiency (1 in 400–800). Connects to our celiac post (IgA deficiency causes false-negative tTG-IgA).
• IgM (40–230 mg/dL): The first responder—the initial antibody produced during acute infection. Elevated IgM on infection-specific testing = acute/recent infection. Also the antibody class in Waldenström's macroglobulinemia.

When to Order Quantitative Immunoglobulins

Order When You See

• Recurrent sinopulmonary infections (2+ pneumonias in a year, 4+ ear infections, chronic sinusitis requiring antibiotics) — evaluate for humoral immunodeficiency
• Suspected primary immunodeficiency: CVID (common variable immunodeficiency), selective IgA deficiency, X-linked agammaglobulinemia in boys
• Monoclonal gammopathy workup: SPEP shows an M-spike — quantitative Igs help characterize suppression of uninvolved immunoglobulins (immune paresis)
• Multiple myeloma monitoring: Suppressed uninvolved Igs (immune paresis) = worse prognosis and higher infection risk
• Autoimmune hepatitis evaluation: Elevated IgG is part of the diagnostic criteria (with ANA/SMA/anti-LKM)
• Suspected Waldenström's macroglobulinemia: Markedly elevated IgM with lymphoplasmacytic infiltration
• Before starting rituximab or other B-cell depleting therapy: Baseline Ig levels for monitoring secondary hypogammaglobulinemia
• Celiac workup with negative tTG-IgA: Check total IgA to rule out IgA deficiency

The Patterns

Pattern	IgG	IgA	IgM	Think About
All low (panhypogamma)	↓	↓	↓	CVID, X-linked agammaglobulinemia (boys), secondary causes (rituximab, myeloma treatment, nephrotic syndrome protein loss, chronic lymphocytic leukemia)
Selective IgA deficiency	Normal	↓↓ (<7 mg/dL)	Normal	Most common primary immunodeficiency. Usually asymptomatic. Associated with celiac disease, autoimmune conditions, and anaphylaxis to blood products containing IgA.
One Ig markedly elevated, others suppressed	One ↑↑↑, others ↓			Monoclonal gammopathy / myeloma. The elevated Ig is monoclonal (M-protein). Confirm with SPEP + immunofixation. Suppression of uninvolved Igs = "immune paresis."
All elevated (polyclonal)	↑	↑	↑	Chronic infections (HIV, HCV, TB), autoimmune diseases (SLE, RA, Sjögren's), chronic liver disease (cirrhosis), sarcoidosis
IgG elevated, others normal	↑↑	Normal	Normal	Autoimmune hepatitis (type 1), chronic infections, connective tissue diseases
IgM markedly elevated	Normal/↓	Normal/↓	↑↑↑	Waldenström's macroglobulinemia, primary biliary cholangitis (moderate IgM elevation), acute infection (transient)
IgA elevated	Normal	↑↑	Normal	IgA nephropathy, alcoholic liver disease, celiac disease (paradoxically, some celiac patients have elevated IgA), mucosal infections

The Myeloma Connection: Immune Paresis

Critical Pattern

In multiple myeloma, the malignant plasma cells produce massive amounts of one monoclonal immunoglobulin while suppressing normal immunoglobulin production. This means: IgG myeloma = very high IgG (monoclonal) with very low IgA and IgM. IgA myeloma = very high IgA (monoclonal) with very low IgG and IgM. Light chain myeloma = all immunoglobulins may be low (the paraprotein is free light chains only, not measurable as intact Ig). Immune paresis (suppressed uninvolved Igs) is a hallmark of myeloma and is the reason these patients have severe infection susceptibility. IgG <500 mg/dL in a myeloma patient indicates high infection risk and may warrant immunoglobulin replacement therapy.

CVID: The Primary Immunodeficiency to Know

Common Variable Immunodeficiency is the most clinically significant primary immunodeficiency in adults. Diagnostic criteria: markedly reduced IgG (usually <500) with low IgA and/or IgM, impaired vaccine responses, and exclusion of other causes. Patients present with recurrent sinopulmonary infections, bronchiectasis, autoimmune cytopenias, granulomatous disease, and increased lymphoma risk. Mean age of diagnosis: 20–30s. Many patients are misdiagnosed for years before the Ig levels are checked.

Pediatric Note

Neonates have high IgG (transplacental maternal IgG) that wanes by 3–6 months, creating a physiologic nadir. Transient hypogammaglobulinemia of infancy is a delayed maturation of IgG production that self-resolves by 2–4 years—distinguish from true primary immunodeficiency by the child's ability to make specific antibodies to vaccines. X-linked agammaglobulinemia (Bruton's) presents in boys at 6–12 months when maternal IgG wanes, with all Ig classes virtually absent and no circulating B cells.

Selective IgA Deficiency: The Autoimmune Crossover

IgA deficiency (<7 mg/dL with normal IgG and IgM) connects to multiple posts in this series:

• Celiac disease: IgA deficiency causes false-negative tTG-IgA; always check total IgA with celiac screening
• Autoimmune associations: Higher prevalence of SLE, RA, thyroiditis, and type 1 diabetes
• Transfusion risk: Rare patients develop anti-IgA antibodies, causing anaphylaxis to blood products containing IgA. Use IgA-deficient or washed blood products if anti-IgA antibodies are documented.
• Most IgA-deficient patients are completely asymptomatic and require no treatment.

The Pitfalls

• Don't confuse quantitative Igs with SPEP: Quantitative Igs measure total amounts. SPEP separates proteins by electrophoretic pattern and detects monoclonal spikes. Both are needed for myeloma workup—they answer different questions.
• A "normal" IgG in myeloma patients is misleading: The total IgG may appear normal because the monoclonal IgG is included in the total. Subtract the M-spike from the total IgG to get the uninvolved (polyclonal) IgG, which is often severely depleted.
• Secondary hypogammaglobulinemia is increasingly common: Rituximab, anti-CD38 antibodies (daratumumab), CAR-T therapy, and chronic corticosteroids all cause IgG suppression. Monitor Ig levels in these patients and consider replacement when IgG <400–500 with recurrent infections.
• Age-dependent norms in children: Pediatric Ig levels change dramatically with age. Use age-specific reference ranges. Neonatal IgG is high (maternal); IgM is low (produced by the infant, not transplacental).

Bottom Line

Quantitative immunoglobulins are essential for evaluating recurrent infections, characterizing monoclonal gammopathies, monitoring immunosuppressive therapy, and diagnosing primary immunodeficiencies. One Ig massively elevated with others suppressed = think myeloma. All Igs low = think CVID or secondary immunodeficiency. Selective IgA deficiency = check for celiac and autoimmune associations. And always use age-appropriate norms in children.

Stay sharp out there.

Allergy Testing: Specific IgE, Skin Prick, Component Testing, and Why Large Panels Create More Problems Than They Solve

 

Allergy Testing: Specific IgE, Skin Prick, Component Testing, and Why Large Panels Create More Problems Than They Solve

A positive allergy test doesn't mean allergy. Sensitization ≠ clinical allergy. And shotgun IgE panels are how patients end up on unnecessary elimination diets.

The Fundamental Principle

Sensitization ≠ Clinical Allergy. A positive specific IgE or skin prick test means the patient has IgE antibodies against that allergen (sensitization). It does NOT mean they will have a clinical reaction on exposure. Up to 50–60% of food-specific IgE positives are clinically irrelevant. The test must ALWAYS be interpreted in the context of clinical history.

The Tests

Skin Prick Testing (SPT)

The clinical gold standard for aeroallergen and food allergy testing. Immediate (15–20 minute) wheal-and-flare response. Advantages: rapid, inexpensive, high sensitivity. Limitations: must stop antihistamines 3–7 days prior; cannot perform on patients with severe eczema, dermatographism, or anaphylaxis risk; requires trained personnel.

Serum Specific IgE (sIgE)

Blood test measuring IgE antibodies to specific allergens. Advantages: not affected by antihistamines, safe in any patient, no risk of anaphylaxis during testing. Limitations: measures sensitization, not clinical allergy. Higher values correlate with higher probability of clinical allergy but are not diagnostic on their own.

Total IgE

Often ordered but rarely helpful. Total IgE is elevated in atopic disease, parasitic infections, allergic bronchopulmonary aspergillosis (ABPA), hyper-IgE syndrome, and some immunodeficiencies. It does NOT identify specific allergens. A normal total IgE does NOT exclude allergy. Avoid ordering total IgE as a screening test for allergy.

Component-Resolved Diagnostics (CRD)

The newest and most clinically useful advance. Instead of testing against whole allergen extracts, CRD tests for IgE against specific allergenic proteins (components). This distinguishes true clinical allergy from cross-reactivity. Example: a patient positive for peanut sIgE may be reacting to Ara h 2 (high risk for clinical anaphylaxis) vs. Ara h 8 (a birch pollen cross-reactive protein that rarely causes significant reactions). CRD changes management—the Ara h 2-positive patient needs an EpiPen; the Ara h 8-positive patient may safely eat peanuts.

The Pitfalls

The Large-Panel Trap

Ordering a 50-food IgE panel on a patient with vague GI symptoms will generate multiple false-positive results (given the 50–60% sensitization-without-allergy rate), leading to unnecessary food elimination diets that impair nutrition, increase anxiety, and reduce quality of life—especially in children. Test only for allergens suggested by the clinical history. Targeted testing based on symptoms, timing, and food diary is far more useful than shotgun panels.

• IgG food testing is not validated: IgG to foods represents normal immune exposure, not allergy. Multiple medical societies (AAAI, EAACI, CAS) recommend against IgG food testing. It has no role in allergy diagnosis.
• Negative tests don't always exclude allergy: Skin prick testing and specific IgE have false-negative rates, particularly for drug allergy and some food allergies (e.g., alpha-gal/red meat allergy requires specific testing for galactose-alpha-1,3-galactose IgE).
• Drug allergy testing is limited: Penicillin skin testing is the only well-validated drug allergy test. For most other drugs, diagnosis relies on clinical history and controlled challenge. Specific IgE for drugs is available for a few agents but has limited sensitivity.
• Antihistamines suppress skin testing but not sIgE: If the patient can't stop antihistamines, use serum specific IgE instead of SPT.

Pediatric Note

Food allergy is most common in young children (milk, egg, wheat, soy, peanut, tree nut). Many children outgrow milk, egg, wheat, and soy allergies by school age. Serial specific IgE levels trending downward predict tolerance development. Peanut and tree nut allergies are more likely to persist. The 2017 NIAID guidelines recommend early peanut introduction (4–6 months) in high-risk infants (severe eczema or egg allergy) after appropriate evaluation—this has been shown to prevent peanut allergy development.

When to Refer to Allergist

• History of anaphylaxis
• Suspected food allergy in a child (for supervised oral food challenge)
• Venom allergy (for immunotherapy evaluation)
• Drug allergy testing (penicillin skin test, desensitization protocols)
• Refractory allergic rhinitis or asthma not responding to empiric treatment
• Suspected ABPA (asthma + bronchiectasis + elevated IgE + Aspergillus sensitization)

Bottom Line

Allergy testing detects sensitization, not necessarily clinical allergy. Test based on clinical history, not as a screening panel. Avoid IgG food testing entirely. Use component-resolved diagnostics when available for food allergy risk stratification. And resist the urge to order large IgE panels for nonspecific symptoms—they generate false positives that lead to unnecessary dietary restrictions and patient harm.

Stay sharp out there.

SPEP, UPEP, Immunofixation, and Free Light Chains: The Myeloma Workup NPs Need to Know

 

SPEP, UPEP, Immunofixation, and Free Light Chains: The Myeloma Workup NPs Need to Know

The dipstick misses light chains. SPEP finds the spike. UPEP catches what spills into the urine. And free light chains changed everything.

This post complements the immunoglobulin levels post and the SPEP section from the autoimmune serologic review. When you suspect a monoclonal gammopathy—whether it's MGUS, multiple myeloma, Waldenström's, or amyloidosis—you need to understand the full diagnostic panel: SPEP, UPEP, immunofixation, and serum free light chains.

The Diagnostic Panel

Test	What It Does	When to Order
SPEP (Serum Protein Electrophoresis)	Separates serum proteins by charge. Detects and quantifies an M-spike (monoclonal protein) in the gamma region.	Suspected myeloma, MGUS screening, unexplained elevated total protein, unexplained proteinuria, polyclonal gammopathy evaluation
Immunofixation (IFE)	Identifies the heavy chain (IgG, IgA, IgM) and light chain (kappa or lambda) type of the monoclonal protein.	Confirm and characterize any M-spike seen on SPEP. More sensitive than SPEP for detecting small monoclonal proteins.
Serum Free Light Chains (sFLC)	Measures kappa and lambda free light chains and calculates the kappa/lambda ratio.	Essential for light chain myeloma, AL amyloidosis, and non-secretory myeloma where SPEP may be negative. Also used for MGUS risk stratification and monitoring.
UPEP (Urine Protein Electrophoresis)	Detects monoclonal protein (Bence Jones protein = free light chains) in urine. Requires 24-hour urine collection.	Myeloma workup, AL amyloidosis, monitoring light chain excretion post-treatment. Detects the light chains the dipstick misses.
Urine Immunofixation	Identifies the type of monoclonal protein in urine (kappa vs. lambda).	Confirm any monoclonal band on UPEP

Why the Dipstick Misses Myeloma

Critical Connection to Urinalysis Post

As discussed in the urinalysis post, the urine dipstick detects albumin only. It does NOT detect free light chains (Bence Jones protein). A patient with light chain myeloma can have massive proteinuria on a 24-hour collection with a completely negative dipstick. This is why UPEP or urine immunofixation is essential in the myeloma workup. If you suspect myeloma, never rely on the dipstick to assess proteinuria.

The Screening Panel for Suspected Myeloma

Per current IMWG (International Myeloma Working Group) guidelines, the recommended initial workup when you suspect a plasma cell neoplasm is:

1. SPEP + serum immunofixation
2. Serum free light chains (kappa and lambda with ratio)
3. 24-hour UPEP + urine immunofixation

Together, these three tests detect >99% of myeloma cases. Using SPEP alone misses ~15–20% of cases (light chain only and non-secretory myeloma).

When to Suspect Myeloma in Primary Care

Red Flags That Should Trigger the Workup

• Unexplained anemia (especially normocytic) + elevated total protein or globulin gap
• Bone pain (especially back, ribs) without clear mechanical cause + anemia
• Unexplained renal insufficiency (especially with bland urine sediment and proteinuria)
• Hypercalcemia without obvious cause
• Markedly elevated ESR (>100 mm/hr) with rouleaux on peripheral smear
• Recurrent bacterial infections with low immunoglobulins
• Peripheral neuropathy without other explanation (think AL amyloidosis)
• Incidental M-spike on SPEP ordered for another reason
• Pathologic fractures or lytic bone lesions on imaging

MGUS: The Precursor State

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre-malignant condition found in ~3% of adults >50. It progresses to myeloma at ~1% per year. MGUS criteria: M-protein <3 g/dL, bone marrow plasma cells <10%, no end-organ damage (CRAB: Calcium elevation, Renal insufficiency, Anemia, Bone lesions). Risk stratification uses: M-protein size, non-IgG isotype, and abnormal free light chain ratio. Low-risk MGUS can be monitored in primary care with annual SPEP, CBC, creatinine, and calcium.

Free Light Chains: The Game-Changer

Serum free light chains revolutionized myeloma diagnostics. Normal kappa/lambda ratio is approximately 0.26–1.65. An abnormal ratio indicates clonal light chain production. FLC is the most sensitive test for detecting light chain myeloma, AL amyloidosis, and non-secretory myeloma—conditions that SPEP and UPEP may miss. The "involved/uninvolved" FLC ratio is also used for monitoring treatment response and detecting early relapse.

The Pitfalls

• FLC ratio is affected by renal function: In CKD, both kappa and lambda accumulate, and the ratio may be mildly abnormal (kappa/lambda up to 3.1 in renal failure) without a clonal process. Use renal-adjusted reference ranges.
• SPEP can miss small M-proteins: Immunofixation is more sensitive. If SPEP is negative but clinical suspicion is high, the immunofixation and FLC may still be positive.
• Don't confuse polyclonal gammopathy with myeloma: A broad-based elevation in the gamma region = polyclonal (autoimmune disease, chronic infection). A narrow spike = monoclonal (MGUS, myeloma, Waldenström's). Immunofixation distinguishes them definitively.
• Urine collection errors: UPEP requires a complete 24-hour collection. Incomplete collections underestimate proteinuria. Some centers now accept a random urine immunofixation for screening, but 24-hour quantification is still needed for monitoring.
• IgA myeloma is harder to quantify on SPEP: IgA M-proteins migrate in the beta region and may be missed or under-quantified. Quantitative IgA and FLC are important adjuncts for monitoring IgA myeloma.

Bottom Line

The myeloma workup requires three tests: SPEP with immunofixation, serum free light chains, and 24-hour UPEP with urine immunofixation. Using any one alone will miss cases. The urine dipstick is blind to light chains. Free light chains are the most sensitive test for light chain disease. And a monoclonal spike on SPEP in a patient over 50 is MGUS until proven otherwise—but it requires monitoring because 1% per year will progress to myeloma.

Stay sharp out there.

Prenatal Labs Deep Dive: First Trimester Through Delivery

 

Prenatal Labs Deep Dive: First Trimester Through Delivery

NIPT sensitivity by condition, the GDM screening controversy, Rh typing pitfalls, and the labs that must happen three times now.

First Prenatal Visit Labs

Test	Why	Key Pitfall
CBC	Screen for anemia, thrombocytopenia, establish baseline MCV	Physiologic anemia of pregnancy (hemodilution) begins in 2nd trimester; don't treat mild drops in Hgb without iron studies
Blood type + Rh + antibody screen	Identify Rh-negative mothers; detect alloantibodies that could cause hemolytic disease of the newborn	Rh-negative mothers need RhoGAM at 28 weeks AND within 72 hours of delivery if baby is Rh-positive. Also after any sensitizing event (miscarriage, amniocentesis, trauma, ectopic).
HIV (4th-gen)	Universal screening. Early detection enables treatment to prevent vertical transmission.	Opt-out screening is the standard. Repeat in 3rd trimester for high-risk patients.
Syphilis (RPR or treponemal screen)	Universal. Now recommended ×3: first visit, 28 weeks, delivery.	Congenital syphilis has surged. Missing this kills babies. Non-negotiable ×3 screening.
Hepatitis B (HBsAg)	Identify carriers for neonatal prophylaxis (HBIG + vaccine at birth)	Even vaccinated mothers can be carriers if vaccination was incomplete or they were infected before vaccination.
HCV antibody	Universal screening in pregnancy per 2020 CDC recommendations	If positive, confirm with HCV RNA. Vertical transmission rate is ~5.8% in viremic mothers.
Rubella IgG	Confirm immunity. Congenital rubella syndrome is devastating.	Cannot vaccinate during pregnancy (live vaccine). If non-immune, vaccinate postpartum.
Urinalysis + culture	Screen for asymptomatic bacteriuria (ASB)—one of the few populations where ASB IS treated	Untreated ASB in pregnancy increases pyelonephritis risk 20–30 fold. Treat all positive cultures.
TSH	Screen for thyroid dysfunction (particularly if symptomatic or high-risk)	Use trimester-specific ranges. TSH normally drops in first trimester from HCG stimulation.
GC/CT NAAT	Screen for gonorrhea and chlamydia at first visit; repeat in 3rd trimester if high-risk	Untreated infections cause preterm labor, neonatal ophthalmia, pneumonia

Prenatal Genetic Screening

Cell-Free DNA (NIPT)

Non-invasive prenatal testing analyzes fetal DNA fragments in maternal blood. Can be done as early as 10 weeks. Now offered to ALL pregnant patients regardless of age or risk (per ACOG 2020).

Condition	Detection Rate	False-Positive Rate	Key Point
Trisomy 21 (Down syndrome)	>99%	<0.1%	Best non-invasive screening test available
Trisomy 18 (Edwards)	97–99%	<0.1%	High detection rate but confirmatory testing still needed
Trisomy 13 (Patau)	87–99%	<0.1%	Slightly lower sensitivity than T21
Sex chromosome aneuploidies	90–97%	Higher than trisomies	Turner's, Klinefelter's, etc. More false positives.
Microdeletions	Variable (60–80%)	Higher	22q11.2 (DiGeorge), 1p36, etc. PPV is LOW in average-risk populations. Many experts caution against routine microdeletion screening.

NIPT Is Screening, Not Diagnostic

A positive NIPT requires confirmatory diagnostic testing (amniocentesis or CVS with karyotype) before any irreversible decisions. NIPT has excellent negative predictive value but the positive predictive value depends on maternal age and prevalence—in low-risk populations, a significant proportion of "positive" results are false positives. Never terminate a pregnancy based on NIPT alone.

First Trimester Screen (Combined)

Nuchal translucency ultrasound + PAPP-A + free beta-hCG (weeks 11–13). Detection rate for T21: ~85%. Being largely supplanted by NIPT but still used in some settings, especially combined with NIPT for higher accuracy or when NIPT is inconclusive.

Quad Screen (Second Trimester)

AFP, hCG, estriol, inhibin A (weeks 15–22). Detection rate for T21: ~80%. Also screens for neural tube defects (elevated AFP) and trisomy 18. Still relevant for patients who present late for care or decline NIPT. Low AFP + other pattern abnormalities = screen positive, not diagnostic.

Gestational Diabetes Screening

The Two Approaches

• One-step (75g OGTT): Fasting, 1-hour, and 2-hour glucose. Used by IADPSG/WHO criteria. One abnormal value = GDM diagnosis. More sensitive, diagnoses more GDM, but debate continues over whether treating the additional cases improves outcomes.
• Two-step (most common in US): 50g glucose challenge test (GCT) as screen (no fasting required); if ≥130–140, follow with 100g 3-hour OGTT. Two abnormal values = GDM. ACOG endorses the two-step approach.

Screen at 24–28 weeks. Screen earlier if high-risk (BMI ≥30, prior GDM, PCOS, strong family history, HbA1c ≥5.7 at first visit). HbA1c is NOT recommended for GDM screening—it lacks sensitivity in pregnancy.

Third Trimester & Delivery Labs

• GBS culture (35–37 weeks): Vaginal-rectal swab. Positive patients receive intrapartum penicillin prophylaxis. GBS is the leading cause of early-onset neonatal sepsis.
• Repeat syphilis: At ~28 weeks and again at delivery. Non-negotiable given the congenital syphilis crisis.
• Repeat HIV: At delivery for high-risk patients or those with no documented test during pregnancy.
• Repeat antibody screen: At 28 weeks in Rh-negative mothers (before RhoGAM administration).
• CBC: Repeat in 3rd trimester to assess for anemia before delivery.

The Pitfalls Summary

• Syphilis screening ×3 is now the standard—a single screen at the first visit is no longer sufficient.
• NIPT is screening, not diagnostic—always confirm positive results with amniocentesis/CVS.
• Microdeletion screening on NIPT has low PPV in low-risk patients—counsel carefully before including these panels.
• HbA1c is not used for GDM screening—use glucose challenge/OGTT.
• Rh-negative mothers need RhoGAM at every sensitizing event, not just at 28 weeks and delivery.
• Asymptomatic bacteriuria in pregnancy MUST be treated—this is the exception to the "don't treat ASB" rule.
• Thyroid ranges are trimester-specific—don't use non-pregnant reference ranges in the first trimester.

Bottom Line

Prenatal labs are a comprehensive, time-sensitive program that runs from the first prenatal visit through delivery. The landscape has shifted with universal HCV screening, triple syphilis screening, NIPT for all pregnancies, and evolving GDM screening approaches. Know the timing, know the confirmatory steps for positive screens, and never miss syphilis or GBS.

Stay sharp out there.

Drug Levels & Therapeutic Monitoring: Timing, Targets, and the Mistakes That Cause Toxicity

 

Drug Levels & Therapeutic Monitoring: Timing, Targets, and the Mistakes That Cause Toxicity

Vancomycin has gone AUC/MIC. Phenytoin needs albumin correction. And lithium levels drawn at the wrong time are useless.

NPs in primary care co-manage patients on narrow therapeutic index medications constantly—anticonvulsants, lithium, digoxin, immunosuppressants, and antibiotics. Getting the timing wrong on a drug level makes the result uninterpretable. Getting the target wrong leads to toxicity or treatment failure.

Quick-Reference: Key Drugs

Drug	Therapeutic Range	When to Draw	Key Pitfall
Vancomycin	AUC/MIC 400–600 (current standard); trough 15–20 is outdated for serious MRSA but still used in some settings	AUC requires 2 levels (1–2 hr post-infusion + trough). For trough-only: draw 30 min before next dose.	AUC/MIC monitoring is now the 2020 ASHP/IDSA guideline standard. Trough-only monitoring overexposes patients to nephrotoxicity.
Digoxin	0.8–2.0 ng/mL (HF benefit at lower range 0.5–0.9)	At least 6 hours post-dose (distribution phase). Ideal: immediately before next dose.	Toxicity risk increases with hypokalemia, hypomagnesemia, hypothyroidism, and renal impairment. Always check K+ and Mg with digoxin levels.
Lithium	0.6–1.2 mEq/L (acute mania: up to 1.5)	12 hours post-dose (standardized timing is critical)	Dehydration, NSAIDs, ACE inhibitors, and thiazides all increase lithium levels. Toxicity is life-threatening. Monitor renal function and TSH regularly.
Phenytoin	10–20 mcg/mL (total); 1–2 mcg/mL (free)	Trough (before next dose). Steady state in 7–10 days.	Correct for albumin: Adjusted phenytoin = measured level / (0.2 × albumin + 0.1). In hypoalbuminemia, total phenytoin is falsely low but the free (active) level may be therapeutic or toxic. Order free phenytoin in hypoalbuminemic or uremic patients.
Valproic acid	50–100 mcg/mL	Trough. Steady state in 2–4 days.	Monitor LFTs and CBC (hepatotoxicity, thrombocytopenia). Highly protein-bound—free levels needed in hypoalbuminemia.
Carbamazepine	4–12 mcg/mL	Trough. Steady state in 2–4 weeks (auto-induction).	Auto-induces its own metabolism—levels drop after 2–4 weeks even at the same dose. Recheck after auto-induction period.
Methotrexate (low-dose)	No routine level monitoring for low-dose (rheumatic/dermatologic use)	N/A for weekly dosing	Monitor CBC, LFTs, creatinine, and albumin. Toxicity manifests as cytopenias, hepatotoxicity, pneumonitis—not as a "high level." Supplement with folic acid 1 mg daily.
Tacrolimus	5–15 ng/mL (varies by organ/time post-transplant)	Trough (12 hours post-dose, immediately before next dose)	Highly variable metabolism. CYP3A4 interactions are extensive (azoles increase levels; carbamazepine, phenytoin decrease). Monitor renal function, glucose, K+, Mg.

The Universal Rules

• Wait for steady state before checking levels (4–5 half-lives after starting or dose change).
• Timing matters: Trough levels are drawn immediately before the next dose. Drawing at the wrong time makes the result uninterpretable.
• Always check renal function with renally cleared drugs (vancomycin, lithium, digoxin, methotrexate).
• Always check albumin with highly protein-bound drugs (phenytoin, valproic acid).
• Drug interactions: CYP450 inducers (carbamazepine, phenytoin, rifampin) lower levels of co-administered drugs. CYP450 inhibitors (azoles, macrolides, grapefruit) raise them.

Bottom Line

Drug level monitoring is about timing, context, and correction factors. A phenytoin level without albumin correction is meaningless. A lithium level drawn 4 hours post-dose is uninterpretable. A vancomycin trough without considering AUC/MIC is outdated. And for methotrexate, you don't monitor levels—you monitor toxicity through labs. Get the timing right, check the renal function, and always ask "is this level drawn correctly?"

Stay sharp out there.